SEO URLwww.firestrike.ai/deals/rapt-therapeutics-gsk-acquisition-2026-5

acquisitionAnnounced · Mar 3, 2026BiopharmaceuticalSource · CredibleArticle · Factual

RAPT Therapeutics · GSK

GSK acquires RAPT Therapeutics

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$2.2B

Target

RAPT Therapeutics

NASDAQ: RAPT · South San Francisco, California

Acquirer

GSK

Full Acquisition

Status

Completed

GSK agreed to acquire RAPT Therapeutics. Reported deal value: $2.2B. Status: Completed. Sector: Biopharmaceutical. Target headquarters context: South San Francisco, California, United States.

This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.

Issued: London , UK For media and investors only GSK completes acquisition of RAPT Therapeutics GSK plc today announced the completion of its previously announced acquisition of RAPT Therapeutics , a California -based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases

Deal timeline

Announced

Mar 3, 2026 · gsk.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in Biopharmaceutical with a reported deal value of $2.2B. Figures and status may change as sources update.

Sources: gsk.com · Primary article · FireStrike proprietary index